What Is Tabimorelin? Definition and What Research Reports

Definition

Tabimorelin is the generic name of an investigational synthetic compound that acts at the growth hormone secretagogue receptor (GHS-R), the receptor through which the hormone ghrelin signals. In the published literature it is labelled a ghrelin-receptor ligand and, in analytical chemistry work, a ghrelin mimetic alongside capromorelin and macimorelin, whose metabolite profiles researchers characterised as potential markers for doping control purposes (PMID 33458843). Tabimorelin also appears in clinical pharmacology papers under the pharmaceutical development code NN703, as in the human study that examined it as a potential inhibitor of CYP3A4 activity (PMID 12610745). There is no approved tabimorelin medicine; the term functions as a research and analytical reference name rather than the name of a marketed product. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, testing or treatment.

What Class of Molecule Is Tabimorelin?

Tabimorelin belongs to the family of compounds usually called growth hormone secretagogues (GHS) — molecules that engage GHS-R, the ghrelin receptor, rather than the growth hormone receptor itself. Two labelling points matter for readers scanning peptide glossaries:

• It is a peptidomimetic, not a peptide. Tabimorelin is a small synthetic molecule designed to imitate the receptor-binding behaviour of a peptide hormone; it is not a naturally occurring amino-acid sequence isolated from tissue. It is nonetheless catalogued with peptide-adjacent secretagogues because of its shared receptor target.
• It is grouped with other "-morelin" compounds. The shared stem reflects the shared receptor family. Analytical work on doping control examined tabimorelin in the same study framework as capromorelin and macimorelin, describing all three as ghrelin mimetics (PMID 33458843).

Where the Name Comes From

The suffix -morelin is the international naming stem used for growth hormone-releasing peptides and secretagogues, which is why tabimorelin sits in the same nomenclature group as macimorelin and capromorelin. The alternative identifier NN703 is a development code, and papers from the early 2000s often print both forms together — for example, the clinical study that paired NN703 (tabimorelin) with midazolam, a CYP3A4 substrate, to probe a possible pharmacokinetic interaction (PMID 12610745). Anyone searching older literature may therefore need both terms to retrieve the full record.

How the Term Is Used in Peptide Research

In practice, "tabimorelin" turns up in three distinct literature contexts, and the meaning shifts slightly with each.

1. As a pharmacological probe of ghrelin-receptor biology

Preclinical papers have used tabimorelin as a tool to ask what happens downstream of ghrelin-receptor activation, and in particular how that signalling interacts with other metabolic pathways. A study in Zucker diabetic fatty (ZDF) rats was framed around exactly this question, testing whether effects of the ghrelin-receptor ligand tabimorelin depended on intact leptin signalling (PMID 15191361).

2. As a clinical pharmacology subject

Because orally administered small molecules can interfere with hepatic drug metabolism, tabimorelin was studied in humans for its potential to inhibit CYP3A4, using midazolam as the marker substrate (PMID 12610745). In this context the term names a candidate drug under pharmacokinetic evaluation rather than a laboratory reagent.

3. As an analytical target in anti-doping science

Sports drug-testing laboratories need to know which metabolites of a compound persist in urine or blood so that tests can detect prior exposure. Researchers reported comprehensive characterisation of the metabolites formed from the ghrelin mimetics capromorelin, macimorelin and tabimorelin and evaluated them as potential markers for doping control purposes (PMID 33458843). Here the term names an analyte, and the discussion is about mass spectrometry and marker selection, not therapy.

What the Published Literature Reports

The verified record summarised on this page is small and heterogeneous. Below is a plain description of what each paper set out to examine and what the researchers reported, without extrapolation.

Reading the rat data carefully

The ZDF rat work is a mechanistic dissociation experiment rather than a clinical efficacy trial. Its interest lies in the interaction it describes: the appetite-related and fat-related responses attributed to ghrelin-receptor activation by tabimorelin were reported to be reduced when leptin signalling was absent, which the authors framed as evidence that these outputs are not fully independent of leptin pathways (PMID 15191361). Rodent metabolic models with genetic leptin-receptor defects do not map directly onto human physiology, and the study did not report human outcomes.

Reading the interaction study carefully

Midazolam is a standard probe substrate used in clinical pharmacology to gauge CYP3A4 activity; pairing an investigational compound with it is a routine way to ask whether the compound alters the metabolism of co-administered drugs. That was the stated purpose of the clinical study of NN703 (tabimorelin) and midazolam (PMID 12610745). The existence of such a study says nothing about benefit and does not establish any approved indication.

Tabimorelin and Adverse Events: What Studies Report

The three verified papers indexed here are not safety trials, and none of them is a pooled tolerability analysis. The clinical paper was designed around pharmacokinetics — specifically the interaction between tabimorelin and midazolam as a CYP3A4 substrate (PMID 12610745) — while the rodent paper addressed adipogenic and orexigenic responses in leptin-signalling-deficient animals (PMID 15191361) and the 2021 paper addressed metabolite identification for testing purposes (PMID 33458843). Accordingly, no adverse-event profile for tabimorelin is characterised on this page, and the absence of reported harms in a small set of mechanistic and analytical papers is not evidence of safety. Questions about risk belong with a licensed clinician and with the full regulatory record, not with a glossary entry.

Common Points of Confusion

• Tabimorelin is not ghrelin. Ghrelin is an endogenous 28-amino-acid hormone; tabimorelin is a synthetic compound described in the literature as a ghrelin-receptor ligand and ghrelin mimetic (PMID 15191361, PMID 33458843).
• Tabimorelin is not macimorelin. The two are separate molecules studied together in metabolite work (PMID 33458843); macimorelin has a marketed diagnostic product in some jurisdictions, whereas tabimorelin has no approved product.
• NN703 and tabimorelin are the same compound. Older clinical pharmacology titles use both names in one line (PMID 12610745).
• A published study is not an endorsement. Doping-control metabolite research exists precisely because a compound may be misused, not because its use is sanctioned.

Limits of the Evidence

The tabimorelin literature summarised here spans nearly two decades and three different research aims, with no large randomised outcome trial among the verified records. Statements about growth hormone responses, body composition, function or long-term safety in humans cannot be drawn from a rat mechanistic study, a single-substrate interaction study and an analytical metabolite paper. Readers comparing glossary entries across the growth hormone secretagogue class should note that evidence depth varies enormously between compounds, and that tabimorelin sits at the sparse end of that range.

References

• Adipogenic and orexigenic effects of the ghrelin-receptor ligand tabimorelin are diminished in leptin-signalling-deficient ZDF rats (European Journal of Endocrinology, 2004)
• A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate (European Journal of Clinical Pharmacology, 2003)
• Comprehensive insights into the formation of metabolites of the ghrelin mimetics capromorelin, macimorelin and tabimorelin as potential markers for doping control purposes (Biomedical Chromatography, 2021)